Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycobacterium w vs BCG in Superficial Transitional Cell Carcinoma
NCT00694915Phase 2Completed
- Sponsor
- Cadila Pharmaceuticals
- Start
- Aug 2008
- Primary completion
- Mar 2014
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MYCIDAC-C in bladder cancer (2 arms), sponsored by Cadila Pharmaceuticals. Primary endpoints: Clinical Adverse Reactions at 24 months and Recurrence Rate at 24 months. Started Aug 2008; status: completed.
02
Drugs
MYCIDAC-C
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00694915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694915.